Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

G1 Therapeutics Inc

Current price
2 USD 0 USD (0.00%)
Last closed 2 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 103 687 400 USD
Yield for 12 month -67.59 %
21.11.2021 - 28.11.2021

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. Address: 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

+51 301 000 USD

Last Year

+31 476 000 USD

Current Quarter

+12 300 000 USD

Last Quarter

+42 392 000 USD

Current Year

+47 553 000 USD

Last Year

+29 460 000 USD

Current Quarter

+9 224 000 USD

Last Quarter

+40 988 000 USD

Key Figures GTHX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -60 959 000 USD
Operating Margin TTM -133.07 %
PE Ratio
Return On Assets TTM -25.65 %
PEG Ratio
Return On Equity TTM -158.99 %
Wall Street Target Price 9 USD
Revenue TTM 77 888 000 USD
Book Value 0.83 USD
Revenue Per Share TTM 1.55 USD
Dividend Share
Quarterly Revenue Growth YOY -47.8 %
Dividend Yield
Gross Profit TTM 47 553 000 USD
Earnings Share -1.43 USD
Diluted Eps TTM -1.43 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -90.82 %

Dividend Analytics GTHX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GTHX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation GTHX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.8245
Price Sales TTM 1.3312
Enterprise Value EBITDA -1.1345
Price Book MRQ 2.386

Financials GTHX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators GTHX

For 52 weeks

1.08 USD 8.4 USD
50 Day MA 1.44 USD
Shares Short Prior Month 2 435 795
200 Day MA 2.28 USD
Short Ratio 3.81
Shares Short 2 490 852
Short Percent 4.85 %